Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
Status:
Completed
Trial end date:
2019-06-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to describe the 2 year progression-free survival in men with
recurrent PSA-only disease after prostatectomy receiving combined enzalutamide and standard
androgen-deprivation therapy (ADT) with salvage radiation therapy. Eligible men will have
recurrent PSA-only prostate cancer within 4 years of prostatectomy, and a PSA of 0.2 - 4 in
the absence of metastatic disease on CT and bone scans. In addition to standard ADT and
radiation therapy, research participants will take enzalutamide once daily for six months. It
is primarily hypothesized the 2 year PFS rate will be improved with the combined therapy
compared to the historical control data in a similar patients setting.